Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy

Background The clinical use of macrophage colony-stimulating factor, granulocyte colony-stimulating factor (G-CSF), and granulocyte macrophage colony-stimulating factor (GM-CSF) has improved the safety of cytotoxic chemotherapy. However, the overexpression of these CSFs in cancers has been reported to be associated with a poor prognosis in various malignancies. We evaluated the potential of CSF expression as a predictor of clinical outcome in patients with muscle-invasive bladder cancer (MIBC). Methods Consecutive patients (n=58) with MIBC who underwent radical cystectomy (RC) were included in this retrospective study. Treatment-naïve tumor specimens obtained by initial transurethral resection of bladder tumors prior to RC were immunostained with antibodies against macrophage colony-stimulating factor, G-CSF, and GM-CSF. We compared the clinicopathological variables and survival between these groups. Baseline levels of CSFs in the serum and voided urine were quantified using an enzyme-linked immunosorbent assay and compared with the expression of CSFs in the tumor lesions. Results Low expression of GM-CSF in the tumor cells was significantly correlated with a pathological T4 category (vs T2–3; P=0.02). In univariate survival analysis, high G-CSF and low GM-CSF expression in the tumor lesion were associated with poor outcomes. Furthermore, Cox proportional regression analysis revealed that high G-CSF and low GM-CSF expression in the tumor were independent predictors of shorter recurrence-free survival, cancer-specific survival, and overall survival. The levels of CSFs in voided urine were associated with the expression of CSFs in the tumor lesions. Conclusion GM-CSF and G-CSF expression in the tumor lesions obtained by initial transurethral resection are independent predictors of poor outcome in MIBC after RC. Levels of G-CSF and GM-CSF in urine before treatment could be useful in prognostication.

[1]  S. Saxena,et al.  Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[2]  I. Hong Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types , 2016, Experimental & Molecular Medicine.

[3]  M. Wirth,et al.  Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. , 2016, European urology.

[4]  K. Shimada,et al.  Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas , 2016, World Journal of Surgical Oncology.

[5]  L. Liao,et al.  Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Corey,et al.  G-CSF and GM-CSF in Neutropenia , 2015, The Journal of Immunology.

[7]  H. Miyake,et al.  Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy , 2015, International journal of urology : official journal of the Japanese Urological Association.

[8]  Minyong Kang,et al.  Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy , 2015, Scientific Reports.

[9]  A. Pathak,et al.  G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use , 2014, Cancer medicine.

[10]  L. Terracciano,et al.  GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer , 2014, Clinical Cancer Research.

[11]  M. Saito,et al.  Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy , 2014, International journal of urology : official journal of the Japanese Urological Association.

[12]  H. Radzun,et al.  Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma , 2014, Virchows Archiv.

[13]  Y. Kanai,et al.  Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. , 2013, The Journal of urology.

[14]  Jimin Gao,et al.  A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. , 2012, The Journal of urology.

[15]  Y. Lotan,et al.  Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.

[16]  R. Wilcox Cancer-associated myeloproliferation: old association, new therapeutic target. , 2010, Mayo Clinic proceedings.

[17]  Bree L. Dority,et al.  Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia , 2009, Cancer.

[18]  E. Yu,et al.  Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Reșorlu,et al.  Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. , 2007, Urology.

[20]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Naito,et al.  Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells , 1994, Cancer Immunology, Immunotherapy.

[22]  S. Saito,et al.  Mirimostim (macrophage colony‐stimulating factor; M‐CSF) improves chemotherapy‐induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function , 2003, Cancer science.

[23]  D. Carlo,et al.  Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine , 2002, Gene Therapy.

[24]  T. Kitamura,et al.  Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein. , 2002, The Journal of urology.

[25]  M. Tanimoto,et al.  Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Y. Kakehi,et al.  Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies. , 1995, British journal of urology.

[27]  T. Nishi,et al.  Autocrine Growth of Transitional Cell Carcinoma of the Bladder Induced by Granulocyte-Colony Stimulating Factor 1 , 2006 .

[28]  L. Yee,et al.  FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. , 1991, Oncogene.